LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Puma Biotechnology Inc

Închisă

SectorSănătate

3.24

Rezumat

Modificarea prețului

24h

Curent

Minim

3.19

Maxim

3.24

Indicatori cheie

By Trading Economics

Venit

-16M

3M

Vânzări

-13M

46M

P/E

Medie Sector

4.59

54.533

EPS

0.1

Marjă de profit

6.464

Angajați

172

EBITDA

-14M

4M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+33.64% upside

Dividende

By Dow Jones

Următoarele câștiguri

31 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

18M

178M

Deschiderea anterioară

3.24

Închiderea anterioară

3.24

Sentimentul știrilor

By Acuity

21%

79%

39 / 381 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

Puma Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

23 mai 2025, 20:33 UTC

Achiziții, Fuziuni, Preluări

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

24 mai 2025, 08:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 mai 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

24 mai 2025, 07:00 UTC

Câștiguri

Retailers Are Giving Mixed Messages on Prices. What Will s Really Happen at Checkout. -- Barrons.com

23 mai 2025, 21:57 UTC

Acțiuni populare

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

23 mai 2025, 21:15 UTC

Top știri

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 mai 2025, 21:04 UTC

Achiziții, Fuziuni, Preluări

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

23 mai 2025, 20:56 UTC

Top știri
Achiziții, Fuziuni, Preluări

Salesforce Back in Deal Talks With Informatica -- WSJ

23 mai 2025, 20:51 UTC

Top știri

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

23 mai 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

23 mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 mai 2025, 20:41 UTC

Top știri

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

23 mai 2025, 20:28 UTC

Top știri

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

23 mai 2025, 20:06 UTC

Top știri

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

23 mai 2025, 20:06 UTC

Achiziții, Fuziuni, Preluări

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

23 mai 2025, 19:50 UTC

Top știri

Trump's Tariffs: Where Things Stand -- 16th Update

23 mai 2025, 19:28 UTC

Achiziții, Fuziuni, Preluări

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

23 mai 2025, 19:28 UTC

Achiziții, Fuziuni, Preluări

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

23 mai 2025, 19:27 UTC

Achiziții, Fuziuni, Preluări

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

23 mai 2025, 19:20 UTC

Market Talk

Crude Futures Post Modest Weekly Losses -- Market Talk

23 mai 2025, 19:18 UTC

Market Talk

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

23 mai 2025, 18:57 UTC

Top știri

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 mai 2025, 18:54 UTC

Top știri

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

23 mai 2025, 18:53 UTC

Top știri
Achiziții, Fuziuni, Preluări

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

23 mai 2025, 18:52 UTC

Achiziții, Fuziuni, Preluări

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

23 mai 2025, 18:13 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

23 mai 2025, 18:13 UTC

Market Talk

Gold Trades Higher on Reminder of Risk -- Market Talk

23 mai 2025, 18:00 UTC

Top știri

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

23 mai 2025, 17:51 UTC

Market Talk
Câștiguri

Workday Sees Higher Bar for Guidance -- Market Talk

23 mai 2025, 17:42 UTC

Top știri

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

Comparație

Modificare preț

Puma Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

33.64% sus

Prognoză pe 12 luni

Medie 4.33 USD  33.64%

Maxim 7 USD

Minim 2 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPuma Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

3 ratings

1

Cumpărare

1

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

3.07 / 3.075Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

39 / 381 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.